IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 65.91

Change

+0.55 (+0.84)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.69 (+0.50%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.37 (+0.56%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.55 (+0.52%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.28 (+0.31%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.46 (+1.99%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.13 (+0.38%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+1.24 (+1.35%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

N/A

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.36 (+0.60%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.06 (-0.23%)

USD 8.55M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.29% 10% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.29% 10% F 47% F
Trailing 12 Months  
Capital Gain 3.01% 71% C- 48% F
Dividend Return 1.45% 94% A 23% F
Total Return 4.46% 71% C- 37% F
Trailing 5 Years  
Capital Gain 24.31% 57% F 63% D
Dividend Return 8.93% 95% A 27% F
Total Return 33.24% 62% D 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.36% 48% F 49% F
Dividend Return 5.73% 52% F 46% F
Total Return 1.38% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.40% 71% C- 66% D+
Risk Adjusted Return 37.23% 67% D+ 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike